GlassScriptPhysician profile
Jacob Grisham
NPI 1417776196
$2,419.64
in general payments reported to CMS, 2019-2025
19 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $534 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.46 | 2024-2025 | |
| Janssen Biotech, INC. | $320.63 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $317.04 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $258.29 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $223.62 | 2024-2025 | Livdelzi |
| Qol Medical, LLC | $148.73 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $115.73 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.18 | 2024-2025 | Xifaxan, Relistor |
| Genzyme Corporation | $82.70 | 2025 | |
| Phathom Pharmaceuticals, INC. | $71.27 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $61.92 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $60.91 | 2025 | |
| Organon LLC | $58.37 | 2025 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $52.16 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $43.35 | 2025 | Suflave |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $28.06 | 2024 | |
| Boston Scientific Corporation | $20.11 | 2025 | Watchman Flx |
| Novo Nordisk INC | $18.37 | 2025 | Wegovy |
| Pfizer INC. | $16.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Grisham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.